Skip to main content
Caplight Logo









Pathios Therapeutics

Pathios Therapeutics

Private
AbingdonHealthcare & Life Scienceshttps://pathiostherapeutics.com/

Last Round

Series B

Apr 18, 2024

Total Funding Raised

$39.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pathios Therapeutics is a biotechnology company that develops small-molecule G protein-coupled receptor (GPR65) inhibitors for applications in immuno-oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

immunotherapysmall-molecule inhibitorGPR65 inhibitorcancer immunotherapydrug discoverytumor microenvironmentbiotech startupfirst-in-class drugoncology pipelineclinical-stage biotechdrug licensingpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pathios Therapeutics Comparables

Compare Pathios Therapeutics with similar companies based on industry and business-model similarity.

Pathios Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cumulus Oncology
85%
Grey Wolf Therapeutics
78%
Arcus Biosciences
69%

Pathios Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 18, 2024
GrantSep 27, 2023
GrantMar 8, 2021
Series ADec 18, 2019
SeedFeb 6, 2019

Key People

Founding team and executive leadership

Paul G Higham

Chief Executive Officer

Executive Team

Sean Carroll

EA To Exec Chair, CEO CSO

Executive Team

Shelley Cook

Chief Operating Officer

Executive Team

Pathios Therapeutics Investors

Notable investors and investment history

Pathios Therapeutics investors
InvestorRounds
Innovate UKGrant
UK governmentGrant
Innovate UKGrant
Canaan PartnersSeries B, Series A
Brandon CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 1376% MoM, reaching 1.2K.

  • Apr 18, 2024

    $25M round led by Bristol Myers Squibb.

Pathios Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pathios Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pathios Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAbingdon
Employee Range20
Year Founded2017
Last FundingApr 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?